Unknown

Dataset Information

0

Aldosterone receptor antagonists: current perspectives and therapies.


ABSTRACT: Aldosterone is a downstream effector of angiotensin II in the renin-angiotensin-aldosterone system and binds to the mineralocorticoid receptor. The classical view of aldosterone primarily acting at the level of the kidneys to regulate plasma potassium and intravascular volume status is being supplemented by evidence of new "off-target" effects of aldosterone in other organ systems. The genomic effects of aldosterone are well known, but there is also evidence for non-genomic effects and these recently identified effects of aldosterone have required a revision in the traditional view of aldosterone's role in human health and disease. The aim of this article is to review the biological action of aldosterone and the mineralocorticoid receptor leading to subsequent physiologic and pathophysiologic effects involving the vasculature, central nervous system, heart, and kidneys. Furthermore, we outline current evidence evaluating the use of mineralocorticoid receptor antagonists in the treatment of primary aldosteronism, primary hypertension, resistant hypertension, obstructive sleep apnea, heart failure, and chronic kidney disease.

SUBMITTER: Guichard JL 

PROVIDER: S-EPMC3699348 | BioStudies | 2013-01-01

SECONDARY ACCESSION(S): NCT00094302

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | S-EPMC3434275 | BioStudies
2014-01-01 | S-EPMC4297153 | BioStudies
2017-01-01 | S-EPMC5396526 | BioStudies
2010-01-01 | S-EPMC2889888 | BioStudies
1000-01-01 | S-EPMC4778065 | BioStudies
2016-01-01 | S-EPMC4748950 | BioStudies
2020-01-01 | S-EPMC6934213 | BioStudies
2017-01-01 | S-EPMC5920695 | BioStudies
2012-01-01 | S-EPMC3299000 | BioStudies
2017-01-01 | S-EPMC5599782 | BioStudies